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Abstract
　The purpose of this study was to assess the accuracy 
and efficacy of a continuous blood glucose monitoring 
system (artificial endocrine pancreas; STG-22, Nikkiso, 
Co., Ltd., Tokyo, Japan) during pediatric cardiopulmonary 
bypass. Sixteen pediatric patients scheduled to undergo 
cardiovascular surgery with cardiopulmonary bypass (6 for 
atrial septal defects, 8 for ventricular septal defects and 2 
for others, age: 7 months to 13 years, body weight 6.4-55.4 
kg) were enrolled. The glucose sensor line of the artificial 
endocrine pancreas was connected to the venous side of the 
cardiopulmonary bypass circuit and used for continuous 
blood glucose monitoring. We obtained 66 samples for blood 
gas assessment from the cardiopulmonary bypass circuit, 
and i-STAT (Abbott, East Windsor, NJ, USA) was used for 
conventional blood glucose assessment. Data were analyzed 
with simple linear regression analysis using the Bland and 
Altman approach. After cardiopulmonary bypass was started 
and the aortic artery clamped, the blood glucose level rose 
markedly to around 300 mg/dl. Blood sampling via the 
venous side of the cardiopulmonary bypass circuit showed 
that continuous blood glucose monitoring was stable and 
reliable even during pediatric cardiovascular surgery with 
cardiopulmonary bypass. A close correlation (R = 0.97) 
was observed between continuous glucose measurement 
and conventional intermittent glucose measurements. The 
results of this continuous blood glucose monitoring system 
for cardiopulmonary bypass during pediatric cardiovascular 
surgery were highly reliable.
Keywords:  continuous blood glucose monitoring, artificial 
endocrine pancreas, cardiovascular surgery, 
cardiopulmonary bypass, children
Introduction
　Hyperglycemia can cause a number of perioperative 
problems, including cardiac, neurological, and infectious 
complications 1), and often occurs in patients with or without 
diabetes during cardiovascular surgery, especially during 
cardiopulmonary bypass. Intensive insulin therapy (IIT) 
may reduce mortality and morbidity among critically ill 
patients 2 ～5). While the viability of IIT for children has 
been reported 6), variations in blood glucose levels during 
cardiopulmonary bypass (CPB) for children are extensive, 
making control of the blood glucose level difficult. 
Continuous blood glucose monitoring is essential for strict 
glycemic control during pediatric cardiovascular surgery. The 
purpose of this study was to assess the accuracy and efﬁcacy 
of a continuous blood glucose monitoring system (artificial 
endocrine pancreas 7, 8); STG-22, Nikkiso, Co., Ltd., Tokyo, 
Japan) during pediatric CPB.
Methods
　This investigation conformed to the principles outlined 
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in the Declaration of Helsinki. The study protocol was 
approved by the Ethics Committee on Human Studies 
of Tokushima University Hospital, and written informed 
consent was obtained from the parents or legal guardians 
of all children. Sixteen pediatric patients scheduled to 
undergo cardiovascular surgery with CPB were enrolled. The 
diagnoses of the patients were as follows: six atrial septal 
defects, eight ventricular septal defects, one pulmonary 
artery stenosis, one double outlet right ventricle). Complete 
repairs of these anomalies were performed. The patients’ 
characteristics were as follows: age, 7 months to 13 years 
4 months; height, 68.0 to 160.6 cm; weight, 6.4 to 55.4 kg; 
gender (male/female), 8/8. General anesthesia was induced 
using sevoﬂurane, and maintained with sevoﬂurane, fentanyl 
and midazolam. The total dose of fentanyl during CPB was 
from 50 to 100 µg/kg.
　The STG-22 is an original artificial endocrine pancreas 
with a closed-loop glycemic control system that provides 
continuous blood glucose monitoring through a glucose 
sensor electrode, and automatically administers insulin and 
glucose infusions to maintain appropriate blood glucose 
levels 7, 8). The insulin and glucose pumps are computer-
regulated based on a targeted blood glucose value determined 
before operation of the system is started. The STG-22’s 
glucose sensor, which draws blood from the patient at a rate 
of 2 ml per hour, is capable of continuously measuring the 
blood glucose level with its glucose sensor, and automatically 
infuses insulin or glucose to adjust the blood glucose level 
of the patients in accordance with the target glucose value, 
in an adaptation of what we call the “closed loop system”. 
This device provides continuous blood glucose monitoring by 
means of dual lumen catheter blood sampling, a high-quality 
roller pump and a glucose sensor electrode with a glucose 
oxidase membrane. The measured blood glucose levels are 
entered into a computer, and the infusion rate of insulin or 
glucose is determined by an algorithm. In the present study, 
we used this device only for glucose monitoring purposes.
　We developed a novel blood sampling method utilizing an 
artiﬁcial endocrine pancreas via the cardiopulmonary bypass 
circuit 9). The glucose sensor line of the artificial endocrine 
pancreas (STG-22) was connected to the venous side of 
the CPB circuit and used for continuous blood glucose 
monitoring. A radial arterial catheter was also inserted 
to obtain samples for blood glucose determination. The 
blood glucose determination was carried out approximately 
once every thirty minutes, to ensure a stable condition. We 
obtained 66 samples for blood gas assessment from the CPB 
circuit. An i-STAT (Abbott, East Windsor, NJ, USA) was 
used for conventional blood glucose assessment.
　The accuracies of continuous glucose measurements 
(STG-22) and the conventional intermittent glucose 
measurements (i-STAT) were compared by a Bland-Altman 
plot 10, 11). In addition, the values obtained using the two 
methods were subjected to correlation analysis. StatView 
version 5.0 (SAS institute Inc., Cary, NC) was used for the 
statistical analysis. Values were expressed as mean ± SD, and 
P < 0.05 was considered to be statistically signiﬁcant.
Results
　Blood sampling via the venous side of the CPB circuit 
showed that continuous blood glucose monitoring was 
stable and reliable even during pediatric cardiovascular 
surgery with CPB. There were no complications related 
to use of the STG-22. Figure 1 shows two typical cases of 
continuous blood glucose monitoring during cardiovascular 
surgery with cardiopulmonary bypass. We found that 
significant hyperglycemia occurred after initiation of the 
cardiopulmonary bypass using an aortic clamp; the blood 
glucose level increased markedly (maximum blood glucose 
concentration: 255 ± 72 mg/dl). After the aortic de-clamp and 
termination of the CPB, the blood glucose showed a tendency 
to decrease (Figure 1A), but hyperglycemia of around 200 
mg/dl persisted in some cases (Figure 1B).
　A close correlation (r = 0.97) was observed between 
continuous glucose measurement by the STG-22 and 
conventional intermittent glucose measurements (i-STAT) 
(Figure 2, left). The limits of agreement are indicated 
by the dotted line – that is, the interval of two standard 
deviations of the measurement differences either side of the 
mean difference. Significant agreement was also observed 
when the differences between the two measurements were 
plotted against their mean values. Limits of agreement were 
thought to be clinically acceptable, however, continuous 
glucose measurement by the STG-22 tended to be lower than 
conventional intermittent glucose measurements (i-STAT) 
(fixed bias: 30.0; 95% confidence interval: 24.6 - 35.4) 
(Figure 2, right).
Discussion
　This is the first report of continuous blood glucose 
monitoring during cardiovascular surgery for pediatric 
patients. Use of the continuous blood glucose monitoring 
system during CPB for pediatric cardiovascular surgery 
was remarkably reliable. During cardiovascular surgery 
(especially cardiopulmonary bypass), blood glucose levels 
change dramatically, so continuous blood glucose monitoring 
is essential for strict glycemic control during pediatric 
cardiovascular surgery. The artificial endocrine pancreas 
is currently the only continuous blood glucose monitoring 
device in the world, and appears to be a useful option for IIT. 
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Figure 1   Continuous blood glucose monitoring during pediatric cardiovascular surgery with cardiopulmonary 
bypass (two typical examples)
BS: blood sugar, CPB: cardiopulmonary bypass, AO: aorta, VSD: ventricular septal defect, ASD: atrial septal defect
Figure 2  Accuracy of continuous blood glucose monitoring during pediatric cardiopulmonary bypass
Left:  Correlations between continuous glucose measurements (STG-22) and conventional intermittent glucose measurements 
(i-STAT). 
Right:  Differences between the two measurements plotted against their mean (Bland-Altman plot of continuous glucose 
measurements (STG-22) and conventional intermittent glucose measurements (i-STAT)). 
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Our ultimate goal is the establishment of a new, superior, 
perioperative blood glucose control method using an artiﬁcial 
endocrine pancreas during pediatric cardiovascular surgery.
　Hyperglycemia can exacerbate a number of perioperative 
problems, including cardiac, neurologic, and infectious 
complications 1). IIT was reported to reduce mortality and 
morbidity in critically ill adult patients 2～5), especially high-
risk cardiac surgery patients. Regarding pediatric patients, 
some studies have demonstrated that hyperglycemia is a 
predictor of adverse outcomes in pediatric intensive care 
units 12, 13). Srinivasan et al. 12) demonstrated that 86% of 
patients in their pediatric intensive care unit had a glucose 
value > 126 mg/dl at some point during their stay. In addition, 
they showed that the duration of hyperglycemia and the peak 
glucose were associated with mortality. Faustino and Apkon 13) 
also demonstrated an association between hyperglycemia 
and length hospital of stay. The patient population analyzed 
by Srinivasan et al. did not include any postoperative 
cardiac patients. Faustino and Apkon’s population included 
cardiac patients in the postoperative period, but there was no 
subanalysis of this patient population.
　In the field of cardiovascular surgery, the importance of 
controlling postoperative blood glucose values at 200 mg/dl 
or less has been recognized since the late 1990s 14, 15). Since 
then, many reports regarding the usefulness of intensive 
insulin therapy during cardiovascular surgery have been 
published 16～19). In a study by Van den Berghe et al., intensive 
insulin therapy after surgery reduced morbidity and death in 
critically ill patients, most of whom had undergone cardiac 
surgery.
　Regarding glycemic control during cardiopulmonary 
bypass, one study analyzed 1,579 adult patients with diabetes 
who underwent cardiovascular surgery in 2005 20). Among 
patients whose blood glucose levels during cardiopulmonary 
bypass exceeded 360 mg/dl, the mortality increased from 
1.7% to 6%. This is why hyperglycemia of more than 300 
mg/dl should be avoided, even temporarily, if a patient has 
diabetes. Cases with blood glucose levels exceeding 300 mg/
dl may be considered rare, but through continuous monitoring 
we found many cases of blood glucose levels above this value 
during cardiopulmonary bypass.
　Why does hyperglycemia occur during cardiovascular 
surgery (especially during cardiopulmonary bypass)? One 
of the main reasons is suppression of insulin secretion. 
This is caused by a reduction in the pancreatic blood flow, 
the inhibition of β-cell activity of the pancreas due to 
hypothermia, and the increased secretion of insulin counter-
regulatory hormones. Other reasons are intracellular 
disorder of glucose use due to peripheral circulatory failure, 
and inhibition of the glycolytic pathway enzyme due to 
hypothermia 21). We do not use it in this hospital, the effect of 
cardioplegia and priming solution including glucose may be 
thought.
　The reliability and accuracy of continuous blood glucose 
monitoring during and after general surgery with the 
STG-22 has been verified in several studies, such as those 
by Yamashita et al. 22, 23). We examined it during pediatric 
cardiovascular surgery with CPB at this time. In our study, the 
blood glucose levels measured continuously during CPB with 
the STG-22 correlated strongly with measurements obtained 
intermittently with a conventional laboratory glucometer. 
Signiﬁcant agreement was also observed when the differences 
between the two measurements were plotted against their 
mean values, and the results were similar to those obtained 
from previous reports. The accuracy of STG-22 during 
pediatric CPB was conﬁrmed. In addition, when we discuss 
agreement using Bland-Altman plot, evaluation of systematic 
bias (ﬁxed bias and proportional bias) is essential. Because 
95% confidence interval of bias did not include zero, it 
was considered that fixed bias was present. Regarding 
proportional bias, it is necessary to perform regression 
analysis of Bland-Altman plot and examine significance of 
the coefficient of regression. Because a weak correlation 
was shown, it was considered that proportional bias was 
also present in this study. However, proportional bias which 
is growing big in proportion to a true value is a natural 
phenomenon, it is clinically acceptable without an extreme 
difference.
　However, our clinical study had some limitations: (1) the 
sample size was small; (2) the variation of range of age group 
was too broad from infant to junior high school students; (3) 
the depth of anesthesia and/or the dose of opioid given during 
the cardiopulmonary bypass might affect the blood glucose 
level; and (4) the Bland-Altman plot methods only deﬁnes the 
intervals of agreement, it does not say whether those limits 
are acceptable or not. Acceptable limits must be defined a 
priori, based on clinical necessity, biological considerations 
or other goals 24).
　In conclusion, we confirmed that the results from a 
continuous blood glucose monitoring system for CPB 
during pediatric cardiovascular surgery were highly reliable. 
Because insulin secretion during CPB decreases due to 
hypothermia and hypoperfusion, glucose levels change 
extensively. Continuous monitoring enhances awareness of 
typical changes in blood glucose levels during cardiovascular 
surgery for children. This artificial endocrine pancreas 
facilitates the safe use of IIT during pediatric cardiovascular 
surgery.
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